Recently JARDIANCE (Empagliflozin) was approved for use, making it the third in this new class of medications. The first two, Invokana (canagiflozin) and Farxiga (dapagliflozin), have had relatively good acceptance into the marketplace especially with the financial ease they have established to get patients to use the medication. There are more of these medicines on the way as it appears that this class will continue to grow. Interestingly enough, not all SGLT-2s are created equal and as the class grows all of us will benefit from this month’s slide series. Drs. Vivian A. Fonseca, MD, FRCP, Ele Ferrannini, MD, PhD, and Mark Stolar, MD, have pooled their knowledge to provide us with a slide presentation that covers everything from mechanism of action to relative strengths to effects in the elderly and everything else in between. This is the most complete presentation on "Improving Outcomes With SGLT2 Cotransporter Inhibition in Challenging Patients," that we have had the opportunity to share with you.